SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Cullinan Therapeutics, Inc. (CGEM) News

Follow Cullinan Therapeutics, Inc. (CGEM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CGEM Asset equity Sector Markets 90 days 13 Last 8.915 Updated Oct 02, 2026, 10:13 AM UTC Open live news feed Open CGEM chart & news
M Cullinan Therapeutics Starts NDA Submission for Zipalertinib Cullinan Therapeutics has initiated a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy. This submission targets first-l EQUITY | Oct 02, 2026, 10:13 AM UTC M Cullinan Therapeutics Starts FDA NDA for Zipalertinib Combo Cullinan Therapeutics has initiated a New Drug Application via the FDA Real-Time Oncology Review program for zipalertinib plus platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC. This submission is based on EQUITY | Oct 01, 2026, 11:32 PM UTC L Weekly Recap: CLN—978 Dec 2026 data release and HC Wainwright $35 target Cullinan Therapeutics, Inc. (NASDAQ:CGEM) said it will report December 2026 single— and multi—dose CLN—978 data for refractory SLE, hard—to—treat RA and refractory Sjögren’s—with the multi—dose readout flagged as a Q4 20 NEWS | Sep 28, 2026, 11:08 AM UTC L Cullinan Therapeutics Price Target Raised to $35.00/Share From $30.00 by HC Wainwright & Co. Ratings actions from Benzinga: GMT) Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga NEWS | Sep 25, 2026, 11:58 AM UTC L Cullinan Therapeutics Price Target Maintained With a $40.00/Share by BTIG Ratings actions from Benzinga NEWS | Sep 25, 2026, 09:59 AM UTC L CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger Cullinan Therapeutics (CGEM) shares tumbled as much as 12% on Thursday after the company outlined fourth-quarter pipeline updates that pushed rheumatoid arthritis data later than previously signaled.The decline reflected EQUITY | Sep 24, 2026, 07:09 PM UTC L Cullinan Therapeutics outlines Q4 2026 data milestones for CLN-978, velinotamig and CLN-049 Cullinan Therapeutics announced planned Q4 2026 data readouts for CLN-978, velinotamig and CLN-049.Key Highlights:Original SEC Filing: Cullinan Therapeutics, Inc. [ CGEM ] - 8-K - Sep. 24, 2026This is an AI-powered summa REGULATION | Sep 24, 2026, 11:44 AM UTC L Cullinan Therapeutics, Inc. (CGEM) Sets Q4 Data Milestones in Autoimmune and Oncology Cullinan Therapeutics will present multi-dose regimen data for CLN-978 in SLE, RA and Sjögren’s in December, velinotamig SLE data at ACR in November, and updated CLN-049 AML Phase 1 data in December, with plans to initia NEWS | Sep 24, 2026, 11:01 AM UTC L Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in NovemberCLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in DecemberCLN-049 (FLT3 TCE) updated data from the Pha NEWS | Sep 24, 2026, 11:01 AM UTC L CGEM - Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio CGEM - Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio NEWS | Sep 24, 2026, 11:00 AM UTC L CGEM - Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum CGEM - Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum NEWS | Sep 21, 2026, 04:00 PM UTC L Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy NEWS | Sep 13, 2026, 11:15 PM UTC H Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.Monday - September 14Tuesday - September CENTRAL_BANK | Sep 11, 2026, 07:01 PM UTC L CGEM - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CGEM - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results EARNINGS | Aug 06, 2026, 11:00 AM UTC